Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.54 |
| ▸ | CCND1 | P24385 | 11/20 | 0.54 |
| ▸ | MPO | P05164 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405420 | 0.89 | MPO (0.51) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2407917 | 0.88 | HTR2A (0.50) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2409993 | 0.88 | MPO (0.47) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2406277 | 0.88 | CDK4 (0.49) | CDK4CCND1MPOCDK2HTR2A | |
| SCHEMBL2404159 | 0.87 | TACR2 (0.45) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2404552 | 0.85 | MPO (0.49) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2406520 | 0.85 | MPO (0.43) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2407903 | 0.85 | MPO (0.43) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL27817683 | 0.85 | MPO (0.44) | CDK4CCND1MPOHTR2ASLC6A4 | |
| SCHEMBL2404802 | 0.85 | MPO (0.44) | CDK4CCND1MPOHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CDK4 3031/4885CCND1 3178/4885MPO 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.